We were fortunate to have the opportunity to speak with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) following her session entitled: Update on Recent Clinical Trials – Parkinson’s Disease.
Questions
1. Could you give us a brief overview of the role of α-synuclein in the pathogenesis of Parkinson’s disease (PD) and its potential as a therapeutic target? (0:06)
2. What are the advantages and limitations of α-synuclein immunotherapies? (1:03)
3. Could you give us an overview of the rationale for targeting glucagon-like peptide (GLP-1) agonists and progress to date? (2:33)
4. What other therapeutic targets are in advanced clinical development? (4:13)
5. What are the challenges of identifying genetic PD and how are these challenges being met? (4:59)
Disclosures: Prof. Simuni reports receiving grants from NINDS, MJFF and Parkinson’s Foundation; support from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Abbvie, IMPAX, Prevail; and other from Acadia, Abbvie, Accorda , Adamas, Allergan, Amneal, Aptinyx, Denali, General Electric (GE), Kyowa, Neuroderm, Neurocrine, Sanofi, Sinopia, Sunovion, Roche, Takeda, Voyager and US World Meds.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
